Oppenheimer reiterated coverage on TransMedics Group with a new price target
$TMDX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Oppenheimer reiterated coverage of TransMedics Group with a rating of Outperform and set a new price target of $125.00 from $200.00 previously